Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989364 | 1.00 | GPR84 (0.49) | GPR84FFAR1TBXAS1ACACBACACA | |
| SCHEMBL9989984 | 0.93 | GPR84 (0.43) | GPR84FFAR1TBXAS1DUTTET2 | |
| SCHEMBL9989980 | 0.93 | GPR84 (0.43) | GPR84FFAR1TBXAS1DUTTET2 | |
| SCHEMBL3179303 | 0.86 | TET2 (0.38) | GPR84FFAR1DUTTET2KDM4A | |
| SCHEMBL3179292 | 0.86 | TET2 (0.38) | GPR84FFAR1DUTTET2KDM4A | |
| SCHEMBL31240397 | 0.81 | ACACB (0.39) | GPR84FFAR1ACACBACACADUT | |
| SCHEMBL31240225 | 0.81 | ACACB (0.39) | GPR84FFAR1ACACBACACADUT | |
| SCHEMBL11292040 | 0.80 | DUT (0.34) | DUT | |
| SCHEMBL6379670 | 0.80 | DUT (0.34) | DUT | |
| SCHEMBL15902883 | 0.80 | DUT (0.34) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407447-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER | TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-8552215-B2 | Method for producing optically active 2-hydroxy ester and novel intermediate compound | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | CA7, HAO2, HACL2 | GPR84 732/4885FFAR1 419/4885TBXAS1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.